Dana Chase, MD, FACOG

home / authors / dana-chase-md-facog

Articles

Dana Chase, MD, FACOG

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

Dana Chase, MD, FACOG
August 12th 2021

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Read More

Dana Chase, MD, FACOG

Dr. Chase on Utilizing Genetic Testing to Guide Treatment Decisions in Ovarian Cancer

Dana Chase, MD, FACOG
July 19th 2021

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Read More

Dr. Chase on Toxicities With Niraparib in Ovarian Cancer

Dr. Chase on Toxicities With Niraparib in Ovarian Cancer

Dana Chase, MD, FACOG
April 11th 2020

Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.

Read More

Latest Updated Articles

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2 expert is featured in this series.
Published: December 24th 2024 | Updated: January 28th 2025
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis